Skip to main
CRMD

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix Inc. is positioned for substantial growth driven by its product DefenCath, particularly with its expansion into total parenteral nutrition (TPN), which could significantly enhance revenue potential beyond initial forecasts. The company expects a three to fivefold improvement in pricing due to the TDAPA formula, as well as robust sales projections ranging from $100 million to $140 million by 2027, reflecting the growing utilization among outpatient dialysis customers. Additionally, ongoing enhancements in treatment tolerability and the anticipated increase in patient uptake suggest further upside opportunities that are not fully accounted for in current revenue models.

Bears say

Cormedix Inc faces a negative outlook primarily due to its downward revenue guidance for 2026, with projections of $300MM-$320MM falling significantly short of market consensus expectations of $423MM. The anticipated transition to a post-TDAPA Add-On Adjustment starting July 1, 2026, is expected to result in significantly reduced reimbursement and net pricing for its product, DefenCath, particularly impacting the second half of the year. Additionally, competition from generics, such as Heparin, poses further risk to meeting sales projections for catheter lock solutions, suggesting potential challenges in achieving sustainable revenue growth.

CorMedix (CRMD) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 6 analysts, CorMedix (CRMD) has a Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.